ClinicalTrials.gg
CompletedNCT06021054THRIVE-2Updated Aug 13, 2026Results posted

An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)

A Phase 3 interventional study of Veligrotug and Placebo in Thyroid Eye Disease, sponsored by Viridian Therapeutics, Inc.. Completed at 57 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by Viridian Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
188
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Graves Ophthalmopathy with a site in United States — 12 open to participants now, 18 under way, 8 of them phase 3. Graves Ophthalmopathy · United States.

Enrollment
5th of 47
188 · median 84
Started
2023
with 6 others
Phase 3
21 of 53
3 open now
Registered
24th of 53
by date
Lead sponsor
9 of 53
Viridian Therapeutics, Inc.

Among the 53 studies in Graves Ophthalmopathy with a site in United States, this one is the 5th largest by enrollment of the 47 interventional ones that give a count, is one of 7 that started in 2023, is one of 21 in phase 3, and was the 24th registered.

Graves Ophthalmopathy

199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

12 of the 53 studies in Graves Ophthalmopathy with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Graves Ophthalmopathy with a site in United States, or all of them as a file.
02

Study summary

This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, veligrotug (VRDN-001), in participants with chronic thyroid eye disease (TED).

Read the detailed description

This is a randomized (meaning participants will be assigned to study arms by chance), double-masked (meaning study doctor and participant will not know which study arm participant is assigned to), placebo-controlled study that will include participants with chronic TED. The key objectives of this study are to determine if veligrotug (VRDN-001) is efficacious, safe, and tolerable when administered as 5 IV infusions given every 3 weeks for a total of 12 weeks in participants with chronic TED.

03

Conditions studied

  • Thyroid Eye Disease

Keywords

  • Thyroid Eye Disease
  • Thyroid-Associated Ophthalmopathy
  • Dysthyroid Ophthalmopathy
  • Graves Eye Disease
  • Graves Orbitopathy
  • Myopathic Ophthalmopathy
  • Congestive Ophthalmopathy
  • Edematous Ophthalmopathy
  • Infiltrative Ophthalmopathy
  • TED
  • Thyroid-Associated Orbitopathy
  • Graves Disease
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Must have moderate to severe chronic TED with documented evidence of ocular symptoms or signs that began greater than 15 months prior to screening
  • Must have had a clinical diagnosis of TED, with any CAS (0-7)
  • Must agree to use highly effective as specified in the protocol
  • Female TED participants must have a negative serum pregnancy test at screening

Key Exclusion Criteria:

  • Must not have received prior treatment with another anti-IGF-1R therapy
  • Must not have received systemic for any condition, including TED, or selenium within 2 weeks prior to first dose
  • Must not have received other drugs or another agent for any condition, including TED, or any other therapy for TED, within 8 weeks prior to first dose
  • Must not have received radioactive iodine (RAI) treatment within 8 weeks prior to first dose
  • Must not have a pre-existing ophthalmic condition in the study eye that in the opinion of the study doctor would confound interpretation of the study results
  • Must not have had previous orbital irradiation or decompression surgery for TED to the study eye's orbit
  • Must not have inflammatory bowel disease
  • Must not have abnormal baseline audiometry Pure Tone Average (PTA) assessment or history of significant (as determined by the Investigator) ear pathology, relevant ear surgery or hearing loss.
  • Female TED participants must not be pregnant or lactating
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
188 participants (actual)

Study arms

  • Experimental
    Veligrotug

    Participants will receive veligrotug 10 mg/kg as an intravenous (IV) infusion every 3 weeks (Q3W) for 12 weeks.

    Drug: Veligrotug

  • Experimental
    Placebo

    Participants will receive placebo matched to veligrotug as an IV infusion Q3W for 12 weeks.

    Drug: Placebo

Interventions

  • 5 IV Infusions of veligrotug 10 mg/kg

    Also known as: VRDN-001

  • DrugPlacebo

    5 IV Infusions of veligrotug matched placebo

06

What researchers measure

Primary outcomes

  1. Proptosis Responder Rate (PRR) in the Most Proptotic Eye as Measured by Exophthalmometer

    Proptosis response in the most proptotic eye was defined as a reduction of proptosis of ≥2 millimeters (mm) from baseline in the most proptotic eye (without a corresponding increase of ≥2 mm in the other eye) as measured by exophthalmometer. Missing data were imputed with the Multiple Imputation (MI) method.

    Time frame: Baseline to Week 15

Secondary outcomes

  1. Change From Baseline in Proptosis in the Most Proptotic Eye as Measured by Exophthalmometer

    Proptosis was defined as distance between the lateral orbital rim and the most anterior position of the cornea in mm, measured using an exophthalmometer. Missing data were imputed with the MI method.

    Time frame: Baseline, Week 15

  2. PRR in the Most Proptotic Eye, as Measured by Magnetic Resonance Imaging (MRI)/Computed Tomography (CT)

    Proptosis responder in the most proptotic eye by MRI/CT was defined as a reduction of proptosis of ≥2 mm from baseline in the most proptotic eye by MRI/CT (without a corresponding increase of ≥2 mm in the other eye) as measured by MRI/CT. Missing data were imputed using the Exophthalmometer Imputation (EXI) method, as applicable.

    Time frame: Baseline to Week 15

  3. Change From Baseline in Proptosis in the Most Proptotic Eye as Measured by MRI/CT

    Measurement of proptosis was conducted by the central imaging reading center using MRI/CT of the orbits acquired without contrast. Measurements were conducted by 2 independent readers with adjudication if the difference between the 2 primary readers in proptosis measurement exceeded 5% (calculated as the difference divided by the larger measurement). The average of 2 (or 3 if adjudicated) measurements were used for analyses. Missing data were imputed using the EXI method, as applicable.

    Time frame: Baseline, Week 15

  4. Clinical Activity Responder Rate in the Most Proptotic Eye as Measured by Exophthalmometer

    Clinical activity responder in the most proptotic eye was defined as no worsening in clinical activity score (CAS) from baseline in the most proptotic eye without a corresponding increase of ≥2 points in the other eye. Missing data were imputed with the MI method.

    Time frame: Week 15

  5. Overall Responder Rate (ORR) Comprising PRR and Clinical Activity Responder Rate in the Most Proptotic Eye as Measured by Exophthalmometer

    ORR was comprised of PRR in the most proptotic eye (reduction of proptosis of ≥2 mm from baseline in the most proptotic eye \[without a corresponding increase of ≥2 mm in the other eye\]) as measured by exophthalmometer at Week 15 and Clinical Activity Responder rate in the most proptotic eye (no worsening in CAS from baseline in the most proptotic eye without a corresponding increase of ≥2 points in the other eye) as measured by exophthalmometer at Week 15. Missing data were imputed with the MI method.

    Time frame: Baseline to Week 15

  6. Diplopia Responder Rate

    A diplopia responder was defined as having a decrease of ≥1 from baseline for participants with a baseline Gorman subjective diplopia score \>0. Gorman subjective diplopia score (range, 0 to 3) includes 4 categories: no diplopia (absent, scored as 0), diplopia in the primary position of gaze when the participant is tired or awakening (intermittent, scored as 1), diplopia at extremes of gaze (inconstant, scored as 2), and continuous diplopia in the primary or reading position (constant, scored as 3). Missing data were imputed with the MI method.

    Time frame: Week 15

  7. Diplopia Resolution Rate

    Diplopia resolution was defined as reduction in Gorman subjective diplopia score to 0 from baseline for participants with baseline Gorman subjective diplopia score \>0. Gorman subjective diplopia score (range, 0 to 3) includes 4 categories: no diplopia (absent, scored as 0), diplopia in the primary position of gaze when the participant is tired or awakening (intermittent, scored as 1), diplopia at extremes of gaze (inconstant, scored as 2), and continuous diplopia in the primary or reading position (constant, scored as 3). Missing data were imputed with the MI method.

    Time frame: Week 15

07

Results

Posted Aug 13, 2026

Participant flow

As prespecified, data were collected and reported for the participants. Therefore, the 'Ns' reported below = number of participants analyzed regardless of which eye was evaluated. The primary and secondary efficacy analyses and safety analysis were measured in the pre-specified study eye per individual participant.

Participant flow — Overall Study
MilestoneVeligrotugPlacebo
Started12563
Received at least 1 dose of study drug12563
Completed605
Not completed6558
Withdrew: Lost to follow-up41
Withdrew: Non-compliance50
Withdrew: Withdrawal by subject52
Withdrew: Other than specified5055
Withdrew: Death10

Outcome measures

PrimaryProptosis Responder Rate (PRR) in the Most Proptotic Eye as Measured by Exophthalmometer

Proptosis response in the most proptotic eye was defined as a reduction of proptosis of ≥2 millimeters (mm) from baseline in the most proptotic eye (without a corresponding increase of ≥2 mm in the other eye) as measured by exophthalmometer. Missing data were imputed with the Multiple Imputation (MI) method.

Time frame:
Baseline to Week 15
Reported as:
Number · percentage of participants
Proptosis Responder Rate (PRR) in the Most Proptotic Eye as Measured by Exophthalmometer
percentage of participantsVeligrotugPlacebo
Proptosis Responder Rate (PRR) in the Most Proptotic Eye as Measured by Exophthalmometer57.288.22
Statistical analysis
  • Veligrotug vs Placebo · Regression, Logistic · p = <0.0001 · Risk difference (rd): 49.06 · 95% CI 37.71 to 60.40
SecondaryChange From Baseline in Proptosis in the Most Proptotic Eye as Measured by Exophthalmometer

Proptosis was defined as distance between the lateral orbital rim and the most anterior position of the cornea in mm, measured using an exophthalmometer. Missing data were imputed with the MI method.

Time frame:
Baseline, Week 15
Reported as:
Least squares mean · mm
Change From Baseline in Proptosis in the Most Proptotic Eye as Measured by Exophthalmometer
mmVeligrotugPlacebo
Change From Baseline in Proptosis in the Most Proptotic Eye as Measured by Exophthalmometer-2.35 ± 0.16-0.46 ± 0.22
SecondaryPRR in the Most Proptotic Eye, as Measured by Magnetic Resonance Imaging (MRI)/Computed Tomography (CT)

Proptosis responder in the most proptotic eye by MRI/CT was defined as a reduction of proptosis of ≥2 mm from baseline in the most proptotic eye by MRI/CT (without a corresponding increase of ≥2 mm in the other eye) as measured by MRI/CT. Missing data were imputed using the Exophthalmometer Imputation (EXI) method, as applicable.

Time frame:
Baseline to Week 15
Reported as:
Number · percentage of participants
PRR in the Most Proptotic Eye, as Measured by Magnetic Resonance Imaging (MRI)/Computed Tomography (CT)
percentage of participantsVeligrotugPlacebo
PRR in the Most Proptotic Eye, as Measured by Magnetic Resonance Imaging (MRI)/Computed Tomography (CT)46.403.17
SecondaryChange From Baseline in Proptosis in the Most Proptotic Eye as Measured by MRI/CT

Measurement of proptosis was conducted by the central imaging reading center using MRI/CT of the orbits acquired without contrast. Measurements were conducted by 2 independent readers with adjudication if the difference between the 2 primary readers in proptosis measurement exceeded 5% (calculated as the difference divided by the larger measurement). The average of 2 (or 3 if adjudicated) measurements were used for analyses. Missing data were imputed using the EXI method, as applicable.

Time frame:
Baseline, Week 15
Reported as:
Least squares mean · mm
Change From Baseline in Proptosis in the Most Proptotic Eye as Measured by MRI/CT
mmVeligrotugPlacebo
Change From Baseline in Proptosis in the Most Proptotic Eye as Measured by MRI/CT-2.02 ± 0.12-0.35 ± 0.17
SecondaryClinical Activity Responder Rate in the Most Proptotic Eye as Measured by Exophthalmometer

Clinical activity responder in the most proptotic eye was defined as no worsening in clinical activity score (CAS) from baseline in the most proptotic eye without a corresponding increase of ≥2 points in the other eye. Missing data were imputed with the MI method.

Time frame:
Week 15
Reported as:
Number · percentage of participants
Clinical Activity Responder Rate in the Most Proptotic Eye as Measured by Exophthalmometer
percentage of participantsVeligrotugPlacebo
Clinical Activity Responder Rate in the Most Proptotic Eye as Measured by Exophthalmometer99.5293.56
SecondaryOverall Responder Rate (ORR) Comprising PRR and Clinical Activity Responder Rate in the Most Proptotic Eye as Measured by Exophthalmometer

ORR was comprised of PRR in the most proptotic eye (reduction of proptosis of ≥2 mm from baseline in the most proptotic eye \[without a corresponding increase of ≥2 mm in the other eye\]) as measured by exophthalmometer at Week 15 and Clinical Activity Responder rate in the most proptotic eye (no worsening in CAS from baseline in the most proptotic eye without a corresponding increase of ≥2 points in the other eye) as measured by exophthalmometer at Week 15. Missing data were imputed with the MI method.

Time frame:
Baseline to Week 15
Reported as:
Number · percentage of participants
Overall Responder Rate (ORR) Comprising PRR and Clinical Activity Responder Rate in the Most Proptotic Eye as Measured by Exophthalmometer
percentage of participantsVeligrotugPlacebo
Overall Responder Rate (ORR) Comprising PRR and Clinical Activity Responder Rate in the Most Proptotic Eye as Measured by Exophthalmometer57.256.63
SecondaryDiplopia Responder Rate

A diplopia responder was defined as having a decrease of ≥1 from baseline for participants with a baseline Gorman subjective diplopia score \>0. Gorman subjective diplopia score (range, 0 to 3) includes 4 categories: no diplopia (absent, scored as 0), diplopia in the primary position of gaze when the participant is tired or awakening (intermittent, scored as 1), diplopia at extremes of gaze (inconstant, scored as 2), and continuous diplopia in the primary or reading position (constant, scored as 3). Missing data were imputed with the MI method.

Time frame:
Week 15
Reported as:
Number · percentage of participants
Diplopia Responder Rate
percentage of participantsVeligrotugPlacebo
Diplopia Responder Rate55.5724.70
SecondaryDiplopia Resolution Rate

Diplopia resolution was defined as reduction in Gorman subjective diplopia score to 0 from baseline for participants with baseline Gorman subjective diplopia score \>0. Gorman subjective diplopia score (range, 0 to 3) includes 4 categories: no diplopia (absent, scored as 0), diplopia in the primary position of gaze when the participant is tired or awakening (intermittent, scored as 1), diplopia at extremes of gaze (inconstant, scored as 2), and continuous diplopia in the primary or reading position (constant, scored as 3). Missing data were imputed with the MI method.

Time frame:
Week 15
Reported as:
Number · percentage of participants
Diplopia Resolution Rate
percentage of participantsVeligrotugPlacebo
Diplopia Resolution Rate31.6013.89

Adverse events

Collected over Baseline up to Week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Veligrotug1/125 (0.8%)10/125 (8%)87/125 (69.6%)
Placebo0/63 (0%)3/63 (4.8%)22/63 (34.9%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventVeligrotugPlacebo
EndometriosisReproductive system and breast disorders1/480/21
FatigueGeneral disorders0/1251/63
MeningiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1251/63
UrticariaSkin and subcutaneous tissue disorders0/1251/63
Immune thrombocytopeniaBlood and lymphatic system disorders1/1250/63
VertigoEar and labyrinth disorders1/1250/63
Graves' diseaseEndocrine disorders1/1250/63
Optic neuropathyEye disorders1/1250/63
Retinal detachmentEye disorders1/1250/63
Rhegmatogenous retinal detachmentEye disorders1/1250/63
Most frequent other events
Showing 10 of 20
Most frequent other events
EventVeligrotugPlacebo
Muscle spasmsMusculoskeletal and connective tissue disorders46/1256/63
HeadacheNervous system disorders21/1258/63
AmenorrhoeaReproductive system and breast disorders6/480/21
DiarrhoeaGastrointestinal disorders15/1256/63
FatigueGeneral disorders13/1255/63
Ear discomfortEar and labyrinth disorders12/1252/63
NasopharyngitisInfections and infestations12/1252/63
AlopeciaSkin and subcutaneous tissue disorders12/1255/63
TinnitusEar and labyrinth disorders11/1252/63
Menstruation irregularReproductive system and breast disorders4/480/21

Baseline characteristics

Modified Intent-to-Treat (mITT) population included all randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)VeligrotugPlaceboTotal
Mean50.5 ± 13.5050.7 ± 12.0350.6 ± 12.99
Sex: Female, Male
Sex: Female, Male(Participants)VeligrotugPlaceboTotal
Female9546141
Male301747
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)VeligrotugPlaceboTotal
Race — Asian336
Race — Black or African American14519
Race — White9448142
Race — Multiple202
Race — Unknown011
Race — Not Reported516
Race — Other527
Race — Missing235
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)VeligrotugPlaceboTotal
Ethnicity — Hispanic or Latino15520
Ethnicity — Not Hispanic or Latino9646142
Ethnicity — Unknown224
Ethnicity — Not Reported111021
Ethnicity — Missing101
08

Study locations

57 sites
  • Advancing Research International, LLC
    Los Angeles, California 90023, United States
  • USC Roski Eye Institute
    Los Angeles, California 90089, United States
  • Amy Patel Jain, MD
    Newport Beach, California 92660, United States
  • Stanford Byers Eye Institute
    Palo Alto, California 94303, United States
  • Cockerham Eye Consultants, PC
    San Diego, California 92108, United States
  • Bascom Palmer Eye Institute - Ophthalmology - Miami
    Miami, Florida 33136, United States
  • Sarasota Retina Institute
    Sarasota, Florida 34239, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Family Eye Physicians, Ltd
    Oak Lawn, Illinois 60453, United States
  • Massachusetts Eye and Ear
    Boston, Massachusetts 02114, United States
  • Ophthalmic Consultants of Boston
    Boston, Massachusetts 02189, United States
  • Michigan State University, Department of Neurology
    East Lansing, Michigan 48824, United States
  • Kahana Oculoplastic and Orbital Surgery
    Livonia, Michigan 48152, United States
  • Washington University School of Medicine in St Louis - Ophthalmology
    St Louis, Missouri 63110, United States
  • Steven Leibowitz, MD.
    Las Vegas, Nevada 89144, United States
  • Rutgers - New Jersey Medical School
    Newark, New Jersey 07103, United States
  • The Center for Eye and Facial Plastic Surgery
    Somerset, New Jersey 08873, United States
  • Department of Ophthalmology, University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Wills Eye Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Baylor College of Medicine (BCM) - Ophthalmology
    Houston, Texas 77030, United States
  • Neuro Eye Clinical Trials
    Houston, Texas 77074, United States
  • University of Vermont Medical Center
    Burlington, Vermont 05401, United States
  • Harborview Medical Center
    Seattle, Washington 98104, United States
  • North Shore Private Hospital
    Saint Leonards, New South Wales 2065, Australia
  • CHU Angers
    Angers, 49033, France
  • CHU de Bordeaux - Hôpital Saint-André
    Bordeaux, 33000, France
  • Centre Hospitalier Universitaire De Nantes - G. R. Laennec
    Nantes, 44093, France
  • CH Nice
    Nice, 06000, France
  • Charité - Universitätsmedizin Berlin KöR
    Berlin, 13353, Germany
  • Universitätsklinikum Essen AöR
    Essen, 45122, Germany
  • University Medical Center Freiburg
    Freiburg im Breisgau, 79106, Germany
  • Universitätsmedizin Göttingen
    Göttingen, 37075, Germany
  • Budapest Retina Intezet
    Budapest, H-1133, Hungary
  • Ganglion Orvosi Kozpont
    Pécs, H-7621, Hungary
  • Pecsi Tudomanyegyetem Klinikai Kozpont Szemeszeti Klinika
    Pécs, H-7623, Hungary
  • Uniwersytecki Szpital Kliniczny w Bialymstoku
    Bialystok, 15-276, Poland
  • Oculomedica Sp. z o.o.
    Bialystok, 85-157, Poland
  • Optimum Profesorskie Centrum Okulistyki Sp. z o.o.
    Gdansk, 80-809, Poland
  • Centrum Medyczne Pulawska Sp. z o.o.
    Piaseczno, 05-500, Poland
  • Centrum Medyczne Piasta 47 sp. z o.o.
    Wałbrzych, 58-304, Poland
  • Complexo Hospitalario Universitario de Santiago-Hospital Médico-Cirúrxico de Conxo
    A Coruña, 15706, Spain
  • Centro de Oftalmologia Barraquer (Barraquer Ophthalmology Centre)
    Barcelona, 08021, Spain
  • Hospital La Arruzafa
    Córdoba, 14012, Spain
  • Hospital Universitario Ramón y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario Virgen De La Macarena
    Seville, 41009, Spain
  • Hospital Universitario Virgen del Rocio
    Seville, 41013, Spain
  • Hospital Universitario Y Politécnico La Fe
    Valencia, 46026, Spain
  • Hospital Unviersitario Miguel Servet
    Zaragoza, 50009, Spain
  • Hacettepe Universitesi Tip Fakultesi
    Ankara, 06230, Turkey (Türkiye)
  • Gazi University Medical Faculty Hospital
    Ankara, 06500, Turkey (Türkiye)
  • Akdeniz University Medical Faculty Hospital
    Antalya, 07059, Turkey (Türkiye)
  • Marmara University Faculty of Medicine
    Istanbul, 34854, Turkey (Türkiye)
  • Moorfields Eye Hospital
    London, EC1V 2PD, United Kingdom
  • Imperial College Healthcare NHS Trust - Western eye Hospital
    London, NW1 5QH, United Kingdom
  • St. Thomas' Hospital
    London, SE1 7EH, United Kingdom
  • The Newcastle Upon Tyne Hospitals NHS Foundation Trust
    Newcastle, NEI 4LP, United Kingdom
  • University Hospital Southampton NHS Foundation Trust
    Southampton, SO16 6YD, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Nov 2024, 12 months.

Results were first posted in Aug 2026, 1 year 9 months after primary completion. A results delay was requested in Oct 2025.

Of 29 phase 3 interventional studies under Graves Ophthalmopathy, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 25. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2023
First posted
Sep 1, 2023
StartActual
Nov 1, 2023
Primary completionActual
Nov 4, 2024
CompletionActual
Jul 25, 2025
Results delay requested
Oct 22, 2025
Results first posted
Aug 13, 2026
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06021054
Lead sponsor
Viridian Therapeutics, Inc.
Responsible party
Sponsor
First posted
Sep 1, 2023
Start date
Nov 1, 2023
Primary completion
Nov 4, 2024
Completion
Jul 25, 2025
Results posted
Aug 13, 2026
Last update
Aug 13, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AVE1642

Start the discussion